iifl-logo

Gland Pharma Ltd Historical Data

Add as a Preferred Source on Google
2,861.2
(-0.43%)
Aug 28, 2026|12:19:55 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Karvy Customer: For activating your account click here.

Gland Pharma Ltd Historical Data

28/07/2026calendar-icon
28/08/2026calendar-icon
Date
Open(₹)
High(₹)
Low(₹)
Close(₹)
No. Of Trades(₹)
Total Turnover(₹)
Deliverable Quantity(₹)

29-Jul-2026

2,428.7

2,5502,428.72,543.748,0372,10,39,72,050.85,17,003

30-Jul-2026

2,565

2,5862,4932,51769,2001,88,91,31,856.23,54,194

31-Jul-2026

2,525.3

2,535.92,5002,502.939,12167,16,17,2361,67,906

03-Aug-2026

2,505.6

2,5852,494.12,579.233,3961,28,65,19,330.42,97,486

04-Aug-2026

2,579.2

2,634.32,561.12,583.155,4291,99,57,77,232.74,55,683

05-Aug-2026

2,587.5

2,595.72,531.12,545.136,11276,59,00,567.41,80,217

06-Aug-2026

2,570

2,626.42,5572,608.341,8311,30,99,62,802.52,58,103

07-Aug-2026

2,601

2,619.92,5702,60127,43482,43,87,694.31,92,841

10-Aug-2026

2,632

2,6852,610.12,667.344,3061,91,66,64,133.74,26,998

11-Aug-2026

2,845.5

2,988.42,8082,924.44,85,59725,38,02,40,103.913,28,146

12-Aug-2026

2,924

2,949.92,8602,891.279,1352,12,07,83,453.32,56,488

13-Aug-2026

2,891.1

2,9752,825.52,967.664,7872,31,99,64,492.13,58,824

14-Aug-2026

2,950.4

3,039.82,946.62,970.269,6222,35,80,98,0383,68,295

17-Aug-2026

2,986

2,993.32,859.72,910.246,2791,08,93,57,000.71,59,558

18-Aug-2026

2,904

2,9252,8502,858.630,9511,40,74,92,405.53,46,597

19-Aug-2026

2,852.9

2,881.42,827.52,841.336,25672,53,11,596.71,33,000

20-Aug-2026

2,857.8

2,869.82,8112,82035,4991,59,09,78,653.73,89,005

21-Aug-2026

2,844.8

2,877.92,7922,819.325,48269,05,34,396.11,13,222

24-Aug-2026

2,825

2,8802,7912,801.645,1111,45,95,72,015.33,09,249

25-Aug-2026

2,810.9

2,835.92,776.12,824.617,16539,04,38,133.554,367

26-Aug-2026

2,838.7

2,9152,831.42,903.240,0091,03,89,09,8972,09,702

27-Aug-2026

2,912.9

2,924.42,855.62,873.518,07037,32,46,238.461,236

Gland Pharma: Related NEWS

Gland Pharma Stock Gains 7% as Q3 Revenue Climbs 22.5% to ₹1,695.3 Crore

The European business reported a 54 percent year on year surge in topline during the quarter.

29 Jan 2026|12:20 PM
Read More
Top Stocks for Today - 8th January 2026

Here are some of the stocks that may see significant price movement today: Infosys, Tata Steel, Cipla Limited, etc.

8 Jan 2026|07:31 AM
Read More
Top Stocks for Today - 4th November 2025

Here are some of the stocks that may see significant price movement: Bharti Airtel, Cipla, Gland Pharma, etc.

4 Nov 2025|08:01 AM
Read More
Top Stocks for Today - 14th July 2025

Here are some of the stocks that may see significant price movement today: Avenue Supermarts, BEML, Gland Pharma, etc.

14 Jul 2025|06:30 AM
Read More
Gland Pharma Gets USFDA Clearance for Visakhapatnam Facility

The receipt of the EIR marks the formal closure of the US health regulator’s pre-approval inspection, which was conducted between February 19 and February 25, 2025.

25 Jun 2025|12:07 PM
Read More
Top Stocks for Today - 5th June 2025

Here are some of the stocks that may see significant price movement today: Hindustan Aeronautics, Gland Pharma, REC, etc.

5 Jun 2025|07:53 AM
Read More
Gland Pharma gets USFDA approval for blood pressure drug

Gland Pharma also established that its version is bioequivalent and therapeutically equivalent to the reference listed drug.

4 Jun 2025|03:34 PM
Read More
Gland Pharma Q4 Net Profit Declines 3.1% to ₹186.5 Crore; Revenue Down 7.3% YoY

Gland Pharma net profit was at ₹186.5 crore as against ₹192.4 crore in the year-ago quarter of FY24.

22 May 2025|08:49 AM
Read More
Gland Pharma Gets USFDA Nod for Glaucoma Drug

Gland Pharma has secured exclusive rights as the first-to-file sponsor of this generic product. This makes it eligible for 180 days of marketing exclusivity in the US

30 Apr 2025|03:40 PM
Read More
USFDA Issues Three Observations to Gland Pharma's Visakhapatnam Facility

The FDA conducted the pre-approval inspection (PAI) from Feb. 19, 2025, to Feb. 25, 2025, as part of the regulatory process for sterile APIs.

26 Feb 2025|12:22 PM
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Karvy Customer: For activating your account click here.
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2026, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

ISO certification icon
We are ISO/IEC 27001:2022 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.